Search
Close this search box.

Cystic Fibrosis

ARO-ENaC-1001

STUDY OUTLINE

The dose-escalating study aims to evaluate the safety, tolerability and efficacy of ARO-ENaC in Cystic Fibrosis patients.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Aged 18 or over with a diagnosis of cystic fibrosis.
  • FEV1 between 40% and 90% predicted.
  • No History of organ transplantation.
  • Not pregnant or breastfeeding.

WHAT'S INVOLVED

  • You will be required to attend at least 16 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands.
  • Complete one phone call for up to approximately 16 weeks (please note, there is also up to 28 days in the screening period of the study).

PRINCIPAL INVESTIGATOR

  • Dr Siobhain Mulrennan

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top